Pharion Speciality Medicines

UNIGEF 250 MG is an oral chemotherapy medication containing Gefitinib, used for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. It inhibits cancer cell growth, slows tumor progression, and helps improve patient outcomes and quality of life.

SAMTICA 500 MG is an oral therapy for metastatic castration-resistant prostate cancer. It inhibits CYP17 enzyme, reducing androgen production, slowing tumor growth, controlling disease progression, and supporting improved quality of life in affected patients.

SAMTICA 250 MG is an oral medication used in the treatment of metastatic castration-resistant prostate cancer. It inhibits CYP17 enzyme, reducing androgen production, slowing cancer growth, and helping manage disease progression while improving patient quality of life.

Caludec Bicalutamide 50mg Tablet is prescribed for prostate cancer treatment. It acts as a non-steroidal anti-androgen, blocking testosterone’s effects on cancer cells. This helps slow tumor growth and improve treatment outcomes, often used alongside other hormone therapies.

• Brand Name: Trombonat 25

• Manufacture: Natco Pharma Ltd.

• Generic Name: Eltrombopag

• Strength: 25 mg

• Dosage Form: Film-coated Tablet

• Therapeutic Class: Thrombopoietin Receptor Agonist

• Treatment of chronic immune (idiopathic) thrombocytopenia (ITP) in adults and children ≥1 year who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

• Treatment of thrombocytopenia in patients with chronic hepatitis C to allow initiation and maintenance of interferon-based therapy.

• Treatment of severe aplastic anemia (SAA) in adults with insufficient response to immunosuppressive therapy.

Eltrombopag is a thrombopoietin receptor (TPO-R) agonist. It binds to the transmembrane domain of the TPO receptor (c-Mpl) on megakaryocyte precursors, activating intracellular signaling pathways. This stimulates proliferation and differentiation of megakaryocytes, thereby increasing platelet production.

• ITP (adults): Starting dose 50 mg orally once daily (25 mg once daily in patients of East Asian ancestry). Adjust dose to maintain platelet count ≥50×10⁹/L.

• Chronic Hepatitis C–associated thrombocytopenia: Starting dose 25 mg once daily; adjust based on platelet response.

• Severe Aplastic Anemia: Starting dose 50 mg once daily; may be titrated up to 150 mg once daily.

• Administration: Take on an empty stomach (1 hour before or 2 hours after a meal). Avoid concomitant intake with dairy products or mineral supplements (calcium, magnesium, iron, aluminum) as they reduce absorption.

• Dose adjustments are required based on platelet response and safety profile.

• Supplied in blister packs.

• Pack size: 7 or 14 tablets (25 mg each).

• Store below 30°C.

• Keep in original package to protect from moisture and light.

• Keep out of reach of children.

• Hepatotoxicity: Risk of ALT, AST, and bilirubin elevations; monitor liver function tests before and during therapy.

• Thromboembolic Events: Excessive platelet counts may increase risk; dose adjustments required.

• Bone Marrow Reticulin Formation: Risk of bone marrow fibrosis; monitor blood counts and marrow if indicated.

• Ocular Disorders: Risk of cataracts with long-term therapy.

• Renal Impairment: Use with caution; monitor renal function.

• Drug Interactions: Avoid polyvalent cation-containing medications/foods close to dosing. Eltrombopag is metabolized by UGT1A1 and CYP1A2—use caution with interacting drugs.

• Pregnancy & Lactation: Contraindicated; may cause fetal harm. Avoid breastfeeding.

• Elderly Patients: No specific adjustments, but monitor closely for safety.

• Brand Name: Veenat 400

• Manufacture: Natco Pharma Ltd.

• Generic Name: Imatinib

• Strength: 400 mg

• Dosage Form: Film-coated Tablet

• Therapeutic Class: Antineoplastic agent, Tyrosine Kinase Inhibitor (TKI)

• Treatment of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic, accelerated, or blast crisis phase.

• Treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in adults.

• Treatment of myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR gene rearrangements.

• Treatment of hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL).

• Treatment of gastrointestinal stromal tumors (GISTs) that are KIT (CD117)-positive, unresectable, or metastatic.

• Adjuvant treatment of patients following resection of GIST to reduce recurrence risk.

Imatinib is a selective protein tyrosine kinase inhibitor. It blocks the BCR-ABL tyrosine kinase produced by the Philadelphia chromosome translocation. By inhibiting BCR-ABL and other kinases such as c-KIT and PDGFR, it prevents phosphorylation of target proteins, inhibiting proliferation and inducing apoptosis of malignant cells.

• CML (chronic phase): 400 mg orally once daily.

• CML (accelerated/blast crisis): 600 mg orally once daily (can be divided).

• Ph+ ALL: 600 mg orally once daily.

• MDS/MPD: 400 mg once daily.

• GIST (metastatic/unresectable): 400 mg once daily (may increase to 600–800 mg if progression).

• Adjuvant GIST: 400 mg once daily for up to 3 years.

• Tablets should be taken with a meal and a large glass of water.

• Dose adjustments required for toxicity or hepatic impairment.

• Available in blister packs or bottles.

• Pack size: 30 tablets (400 mg each).

• Store below 30°C, in a dry place.

• Protect from light and moisture.

• Keep out of reach of children.

• Hematologic Toxicity: Risk of neutropenia, thrombocytopenia, and anemia; monitor complete blood counts regularly.

• Hepatic Toxicity: Liver enzyme elevations may occur; monitor liver function tests.

• Fluid Retention/Edema: Common; monitor for rapid weight gain, pleural effusion, or ascites.

• Cardiac Risk: Use with caution in patients with heart disease; risk of congestive heart failure.

• Gastrointestinal Effects: Nausea, vomiting, diarrhea, and abdominal pain are common.

• Pregnancy & Lactation: Contraindicated; can cause fetal harm. Avoid breastfeeding during treatment.

• Drug Interactions: Metabolized by CYP3A4. Avoid strong inhibitors/inducers (ketoconazole, rifampin, St. John’s Wort).

• Elderly Patients: Close monitoring required as adverse events may be more pronounced.

• Brand Name: Trombonat 50

• Manufacture: Natco Pharma Ltd.

• Generic Name: Eltrombopag

• Strength: 50 mg

• Dosage Form: Tablet

• Therapeutic Class: Thrombopoietin Receptor Agonist, Hematopoietic Agent

• Treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) in adults and children ≥1 year who have had insufficient response to corticosteroids, immunoglobulins, or splenectomy.

• Treatment of thrombocytopenia in patients with chronic hepatitis C to allow initiation and maintenance of interferon-based therapy.

• Treatment of severe aplastic anemia (SAA) in patients who are refractory to prior immunosuppressive therapy.

Eltrombopag is a thrombopoietin receptor agonist.

• Binds to the transmembrane domain of the TPO receptor (c-Mpl).

• Stimulates proliferation and differentiation of megakaryocyte progenitor cells.

• Increases platelet production, thereby reducing bleeding risk in patients with thrombocytopenia.

• Initial dose (ITP, adults): 50 mg once daily; may adjust based on platelet response.

• Hepatitis C-related thrombocytopenia: 25 mg once daily, adjusted as per response.

• Severe Aplastic Anemia: Starting dose 50 mg once daily, titrated according to response.

• Taken on an empty stomach (1 hour before or 2 hours after meals).

• Avoid concurrent administration with antacids, dairy, or supplements containing iron, calcium, aluminum, magnesium, selenium, or zinc, as they reduce absorption.

• Therapy should be individualized and monitored with regular platelet counts.

• Supplied in blister packs.

• Pack size: 7 tablets (50 mg each).

• Store at 20°C–25°C.

• Protect from light and moisture.

• Keep container tightly closed.

• Keep out of reach of children.

• Hepatotoxicity: Risk of elevated liver enzymes; monitor liver function before and during therapy.

• Thrombosis Risk: Excessive platelet increase may lead to thromboembolic complications; adjust dose accordingly.

• Bone Marrow Effects: Risk of bone marrow fibrosis with prolonged use; periodic monitoring recommended.

• Cataracts: Reports of cataract formation; ophthalmologic exams advised during long-term therapy.

• Drug Interactions: Avoid polycationic medications (iron, calcium, magnesium supplements) around dosing time.

• Pregnancy & Lactation: Use only if clearly needed; avoid breastfeeding during treatment.

• Pediatric Use: Approved for children ≥1 year with chronic ITP, dosing based on age and weight.

• Discontinuation: Platelet count typically returns to baseline within 1–2 weeks after stopping therapy; patients remain at risk of bleeding.

• Brand Name: Bracanat 150

• Manufacture: Natco Pharma Ltd.

• Generic Name: Olaparib

• Strength: 150 mg

• Dosage Form: Tablet

• Therapeutic Class: Antineoplastic Agent, PARP Inhibitor

• Ovarian Cancer: Maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

• Breast Cancer: Treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer, previously treated with chemotherapy.

• Pancreatic Cancer: In patients with deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma who have received ≥16 weeks of platinum-based chemotherapy without disease progression.

• Prostate Cancer: For deleterious or suspected deleterious germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) following prior therapy.

Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.

• Inhibits PARP-1 and PARP-2, enzymes vital for DNA single-strand break repair.

• Leads to accumulation of DNA damage and double-strand breaks.

• Causes cancer cell death, especially in tumors with BRCA1/2 mutations or homologous recombination deficiency (HRD).

• Standard dose: 300 mg orally twice daily (total 600 mg/day).

• Typically administered as two 150 mg tablets twice daily.

• Tablets should be swallowed whole, not crushed or chewed.

• May be taken with or without food.

• Continue treatment until disease progression or unacceptable toxicity.

• Dose adjustments: May be required for hematologic toxicity, renal impairment, or drug interactions.

• Supplied in blister packs.

• Pack size: 56 tablets (150 mg each).

• Store at 20°C–25°C (room temperature).

• Protect from moisture and light.

• Keep container tightly closed.

• Keep out of reach of children.

• Hematologic Toxicity: Anemia, neutropenia, thrombocytopenia common; CBC monitoring required monthly.

• MDS/AML Risk: Rare but serious cases of myelodysplastic syndrome and acute myeloid leukemia reported.

• Pulmonary Toxicity: Rare cases of pneumonitis; discontinue if confirmed.

• Renal Impairment: Dose modification needed in moderate impairment; avoid in severe renal dysfunction.

• Drug Interactions: Olaparib is metabolized by CYP3A; avoid strong CYP3A inhibitors/inducers. Avoid grapefruit and Seville oranges.

• Pregnancy & Lactation: Contraindicated; may cause fetal harm. Breastfeeding should be avoided.

• Contraception: Effective contraception during and after therapy (6 months for women, 3 months for men).

• Elderly Use: No major differences noted, but monitor carefully.

50 mg Dasatib (Dasatinib) Tablet is used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). It works by inhibiting tyrosine kinase to prevent cancer cell growth and spread.

50 mg Invista (Dasatinib) Tablets are used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). It works by inhibiting tyrosine kinase to block cancer cell growth.

Rebopag 50 mg Tablet contains Eltrombopag, a thrombopoietin receptor agonist used to treat low platelet counts in chronic immune thrombocytopenia (ITP) and aplastic anemia. It works by stimulating platelet production in the bone marrow, reducing bleeding risk and improving blood cell levels.

Rebopag 75 mg Tablet contains Eltrombopag, a thrombopoietin receptor agonist that boosts platelet production in patients with chronic immune thrombocytopenia (ITP) or aplastic anemia. It helps reduce bleeding risk, improve platelet counts, and support better blood cell recovery and overall treatment outcomes.

Invista 70 mg Tablet contains Dasatinib, a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It works by blocking abnormal cancer cell growth and division, helping to control disease progression and improve treatment outcomes.

AHABIR 500 Tablet contains Abiraterone, a potent medication used to treat prostate cancer by inhibiting androgen production. It helps in slowing cancer progression and improving patient outcomes. Recommended for use under medical supervision with regular monitoring.

Capsy Capecitabine Tablet 500 mg is an oral chemotherapy medicine used in the treatment of various cancers, including colorectal and breast cancer. It is a prodrug that converts into 5-fluorouracil in the body, interfering with cancer cell growth and division. The tablet should be taken exactly as prescribed under oncologist supervision.

Daslemia 50 mg Tablet by Intas Pharmaceuticals Ltd contains Dasatinib 50 mg, a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It works by inhibiting BCR-ABL and other kinases, thereby preventing the growth and proliferation of cancer cells.

Geffon 250 mg Tablet by Zydus Cadila contains Gefitinib 250 mg, an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations. It works by blocking EGFR signaling pathways, thereby inhibiting cancer cell growth and progression.

Geffy 250 mg Tablet by Intas Pharmaceuticals Ltd contains Gefitinib 250 mg, an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. It works by blocking EGFR signaling, thereby inhibiting cancer cell growth and progression.

SAMGOLIX 120 MG is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist used to manage advanced prostate cancer. It lowers testosterone levels, helps control disease progression, and improves symptoms while offering convenient once-daily oral dosing.

Caludec Bicalutamide 50mg Tablet is an anti-androgen medicine used in the treatment of prostate cancer. It works by blocking the action of male hormones, slowing cancer cell growth and spread. Taken orally, it is usually prescribed with other therapies for effective cancer management.

Endace Megestrol Acetate 40mg Tablet is used in the treatment of breast and endometrial cancers. It acts as a progestin, slowing cancer growth by altering hormone activity. It also helps improve appetite and weight gain in patients with cancer-related cachexia or significant weight loss.

SORATIB 200 MG is an oral multi-kinase inhibitor used to treat advanced renal cell carcinoma and hepatocellular carcinoma. It works by blocking tumor cell proliferation and angiogenesis, helping slow cancer progression, reduce tumor growth, and improve patient outcomes.

SAMENZA 160 MG is an oral androgen receptor inhibitor used to treat advanced or metastatic prostate cancer. It blocks testosterone’s action on cancer cells, slowing tumor growth, controlling disease progression, and helping manage cancer-related symptoms effectively.

TORINAT 5 contains Everolimus, an oral mTOR inhibitor indicated for the treatment of advanced renal cell carcinoma, hormone receptor–positive breast cancer, pancreatic neuroendocrine tumors, and other selected cancers. By targeting the mTOR pathway, it helps slow cancer cell growth and angiogenesis. Therapy must be taken under strict medical guidance with regular monitoring for safety and treatment effectiveness.

XTANE 25 contains Exemestane, an aromatase inhibitor used in the treatment of hormone receptor–positive breast cancer in postmenopausal women. It works by lowering estrogen levels, slowing the growth of hormone-dependent tumors. Commonly prescribed after other endocrine therapies, this oral tablet should be taken under strict medical supervision with regular monitoring for safe and effective results.

TIPANAT 15 contains Trifluridine and Tipiracil, an oral anticancer combination used for metastatic colorectal cancer and gastric cancer in patients previously treated with other therapies. Trifluridine incorporates into DNA to inhibit cancer cell growth, while Tipiracil increases its effectiveness by preventing breakdown. Taken orally in tablet form, it requires strict medical supervision and regular monitoring for safety and efficacy.

TORINAT 10 contains Everolimus, an mTOR inhibitor used in the treatment of advanced renal cell carcinoma, breast cancer, pancreatic neuroendocrine tumors, and certain other cancers. It works by blocking the mTOR pathway, thereby reducing cancer cell growth, proliferation, and angiogenesis. Administered orally, it requires strict medical supervision with regular monitoring to ensure safe and effective therapy outcomes.

SORAFENAT 200 contains Sorafenib, a multikinase inhibitor used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and certain thyroid cancers. It works by blocking tumor cell proliferation and angiogenesis, thereby slowing disease progression. Administered orally as a tablet, it must be taken under strict medical supervision with regular monitoring to ensure safety and effectiveness.

About the product:

• Brand Name: REGONAT
• Generic Name: Regorafenib
• Strength: 40 mg
• Dosage Form: Tablet
• Therapeutic Class: Multikinase Inhibitor / Anticancer.

Indications:

• Metastatic colorectal cancer (mCRC)
• Gastrointestinal stromal tumor (GIST)
• Hepatocellular carcinoma (HCC)

Mechanism of Action:

• Inhibits multiple protein kinases involved in tumor angiogenesis, oncogenesis, and tumor microenvironment.

Dosage & Administration:

• Usual dose: 160 mg (4 tablets) once daily for 21 days of a 28-day cycle.
• To be taken after a low-fat meal.
• Dose adjustment as per tolerance.

Packaging:

• Bottle of 28 tablets

Storage Instructions:

• Store below 25°C
• Keep in original container, tightly closed
• Protect from moisture

Precautions:

• Use under medical supervision only
• Monitor liver function
• Avoid during pregnancy & breastfeeding
• May cause hand-foot skin reaction, hypertension, fatigue

PAZONAT 400 contains Pazopanib, an oral tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. It works by blocking vascular endothelial growth factor receptors (VEGFR) and other kinases involved in tumor growth and angiogenesis, thereby slowing disease progression. Therapy should be taken strictly under medical supervision with regular monitoring for safety and efficacy.